Effect of a daily dose of Lactobacillus brevis CD2 lozenges in high caries risk schoolchildren

A double-blind, randomised, placebo-controlled clinical trial was performed to validate the hypothesis that the use of lozenges containing Lactobacillus brevis CD2 (InersanA (R), CD Investments srl) may reduce plaque pH, salivary mutans streptococci (ms) and bleeding on probing, during a 6-week period, in a sample of high caries risk schoolchildren. A total of 191 children (aged 6-8 years), presenting two to three carious lesions and a salivary ms concentration of a parts per thousand yen10(5) CFU/ml, were enrolled and divided into two groups, an L. brevis CD2 lozenge group and a no L. brevis lozenge group, and examined at baseline (t(0)), after 3 weeks (t(1)), after 6 weeks of lozenge use (t(2)) and 2 weeks after the cessation of lozenge use (t(3)). Plaque pH was assessed using the microtouch technique following a sucrose challenge. The area under the curve (AUC(5.7) and AUC(6.2)) was recorded. Salivary ms were counted, and bleeding on probing was assessed. At t(0), the plaque-pH and ms concentration values were similar in both groups. Mean areas (AUC(5.7) and AUC(6.2)) were significantly greater in the control group at t(1), t(2) and t(3). L. brevis CD2 lozenges significantly reduced salivary ms concentrations and bleeding. The subjects from the test group showed a statistically significant decrease (p = 0.01) in salivary ms concentration. At t(2), a statistically significantly lower bleeding value was recorded in the test group compared with the control group (p = 0.02). Six weeks' use of lozenges containing L. brevis CD2 had a beneficial effect on some important variables related to oral health, including a reduction in plaque acidogenicity, salivary ms and bleeding on probing. (Trial Registration Number NCT01601145 08/21/2012).